Fosun Pharma Reports Strong Interim Results for First Half of 2026

Fosun Pharma announced its interim results for the first half of 2026, reporting a revenue of RMB 20.442 billion, a year-on-year increase of 4.75%. The company's profit attributable to shareholders, net of non-recurring gains and losses, grew by 19.09% year-on-year to RMB 1.144 billion, indicating sustained improvement in earnings quality.